WO2016073595A8 - T cells and dendritic cells for polyomavirus therapy - Google Patents

T cells and dendritic cells for polyomavirus therapy Download PDF

Info

Publication number
WO2016073595A8
WO2016073595A8 PCT/US2015/059021 US2015059021W WO2016073595A8 WO 2016073595 A8 WO2016073595 A8 WO 2016073595A8 US 2015059021 W US2015059021 W US 2015059021W WO 2016073595 A8 WO2016073595 A8 WO 2016073595A8
Authority
WO
WIPO (PCT)
Prior art keywords
polyomavirus
cells
antigen
disclosed
specific
Prior art date
Application number
PCT/US2015/059021
Other languages
French (fr)
Other versions
WO2016073595A1 (en
Inventor
Austin John BARRETT
Dhanalakshmi Chinnasamy
Pawel MURANSKI
Christopher B. Buck
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Publication of WO2016073595A1 publication Critical patent/WO2016073595A1/en
Publication of WO2016073595A8 publication Critical patent/WO2016073595A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Disclosed herein are dendritic cells (DCs) expressing one or more polyomavirus antigens. In some examples, these modified DCs are transduced with a viral vector (such as a lenti viral vector) encoding the one or more polyomavirus antigens. The modified DCs are in some examples used to produce polyomavirus antigen-specific T cells. Also disclosed are methods of producing polyomavirus antigen-specific T cells by contacting mononuclear cells with a mixture of peptides from a polyomavirus antigen. The antigen-specific T cells or modified DCs may be administered to a subject to induce or enhance an immune response to polyomavirus in the subject, for example to treat or inhibit polyomavirus infection and/or polyomavirus-associated disease in the subject. Also disclosed herein are methods of making the disclosed modified DCs and polyomavirus antigen-specific T cells.
PCT/US2015/059021 2014-11-05 2015-11-04 T cells and dendritic cells for polyomavirus therapy WO2016073595A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462075726P 2014-11-05 2014-11-05
US62/075,726 2014-11-05

Publications (2)

Publication Number Publication Date
WO2016073595A1 WO2016073595A1 (en) 2016-05-12
WO2016073595A8 true WO2016073595A8 (en) 2016-06-23

Family

ID=54540263

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/059021 WO2016073595A1 (en) 2014-11-05 2015-11-04 T cells and dendritic cells for polyomavirus therapy

Country Status (1)

Country Link
WO (1) WO2016073595A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106749552A (en) * 2016-11-21 2017-05-31 深圳市福田区人民医院 WU polyomavirus recombinant antigens and its preparation method and application
US11981923B2 (en) 2022-04-18 2024-05-14 Baylor College Of Medicine Pepmixes to generate multiviral CTLS with broad specificity

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
DK2812431T3 (en) 2012-02-09 2019-10-14 Baylor College Medicine PEPTID MIXTURES FOR GENERATION OF WIDE SPECIFIC MULTIVIRAL CTLS
US11167024B2 (en) 2015-09-18 2021-11-09 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
EP3203237B1 (en) * 2016-02-03 2023-07-05 Nina Babel Urine-derived epithelial cell lines for diagnosis and therapy of an anti-bk-virus or anti-graft immune response
JP7086928B2 (en) 2016-07-25 2022-06-20 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ How to generate and use modified natural killer cells
US10821134B2 (en) * 2017-05-17 2020-11-03 Board Of Regents, The University Of Texas System BK virus specific T cells
EP3740226A4 (en) * 2018-01-19 2021-10-13 The Wistar Institute Of Anatomy And Biology Large and small t antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same
US10772914B1 (en) 2019-04-18 2020-09-15 Baylor College Of Medicine EBV-specific immune cells
CA3148391A1 (en) * 2019-07-24 2021-01-28 The Council Of The Queensland Institute Of Medical Research Immunotherapy for polyomaviruses
EP4347794A1 (en) * 2021-06-02 2024-04-10 Danmarks Tekniske Universitet Person-tailored t cell composition targeting merkel cell carcinoma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2548567A1 (en) * 2011-07-22 2013-01-23 Universitätsklinikum Hamburg-Eppendorf Polyoma virus JC peptides and proteins in vaccination and diagnostic applications

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106749552A (en) * 2016-11-21 2017-05-31 深圳市福田区人民医院 WU polyomavirus recombinant antigens and its preparation method and application
CN106749552B (en) * 2016-11-21 2020-04-07 中山大学附属第八医院（深圳福田） WU polyoma virus recombinant antigen and preparation method and application thereof
US11981923B2 (en) 2022-04-18 2024-05-14 Baylor College Of Medicine Pepmixes to generate multiviral CTLS with broad specificity

Also Published As

Publication number Publication date
WO2016073595A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
WO2016073595A8 (en) T cells and dendritic cells for polyomavirus therapy
MX2022005955A (en) Methods and compositions for adoptive cell therapy.
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
TW201613954A (en) Interleukin-10 fusion proteins and uses thereof
WO2017011804A8 (en) Engineered cells for adoptive cell therapy
EP4219696A3 (en) Oncolytic virus strain
WO2015134722A3 (en) Methods and compositions for increasing a t-effector cell to regulatory t cell ratio
MX2017006571A (en) T cell activating bispecific antigen binding molecules agiant folr1 and cd3.
MX2019014695A (en) Interleukin-2 fusion proteins and uses thereof.
MX2021000435A (en) Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor.
WO2016014565A3 (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor
SG10201803384TA (en) Bispecific t cell activating antigen binding molecules
MX2019012223A (en) Anti-cd137 antibodies and methods of use thereof.
EA201891459A1 (en) NEW GENERATION OF ANTIGENSPECIFIC TCR
WO2016011210A3 (en) Engineered cells for adoptive cell therapy
SG10201903349YA (en) Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
MY187462A (en) Modified virus-like particles of cmv
MY171687A (en) Pr13.5 promoter for robust t-cell and antibody responses
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
MX2018004598A (en) Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy.
WO2015112749A3 (en) Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
MX354516B (en) Vectors encoding rod-derived cone viability factor.
EA201591791A1 (en) MAN PAC1 ANTIBODIES
ZA202206809B (en) Hiv vaccines comprising one or more population episensus antigens
AU2016335217A8 (en) Antigen receptors and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15794038

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15794038

Country of ref document: EP

Kind code of ref document: A1